RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1243-1250

  Tang, Zhen Ning ^a   Zhang, Fan ^a   Tang, Peng ^a   Qi, Xiao Wei ^a   Jiang, Jun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Migration; Receptor activator of nuclear factor B; Receptor activator of nuclear factor B ligand; Src

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPROTEGERIN; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; VIRUS VECTOR;

ARTICLE; BREAST CANCER; CELL ASSAY; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; OSTEOCLASTS; RANK LIGAND; RNA, SMALL INTERFERING; SRC-FAMILY KINASES; TRANSFECTION;

EID: 80053135821     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1368     Document Type: Article

References (30)

1. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
2. Rose AA and Siegel PM: Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6: 55-74, 2010.
3. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J and Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. (Pubitemid 28180851)
4. Leibbrandt A and Penninger JM: RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 1143: 123-150, 2008.
5. Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D and Redini F: RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 28: 261-269, 2006.
6. Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, Redini F and Heymann D: Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 18: 1365- 1371, 2007.
7. Hsu CJ, Lin TY, Kuo CC, Tsai CH, Lin MZ, Hsu HC, Fong YC and Tang CH: Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration. J Cell Biochem 111: 138-147, 2010.
8. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T and Penninger JM: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
9. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D and Redini F: DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40: 981-990, 2007. (Pubitemid 46386537)
10. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104, 2008.
11. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M and Okada Y: Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218: 530-539, 2009.
12. Henriksen K, Karsdal M, Delaisse JM and Engsig MT: RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278: 48745-48753, 2003. (Pubitemid 41079516)
13. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ and Dougall WC: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25: 119-129, 2008.
14. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G and Penninger JM: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102, 2010.
15. Rucci N and Teti A: Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2: 907-915, 2010.
16. Hall CL, Bafico A, Dai J, Aaronson SA and Keller ET: Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65: 7554-7560, 2005. (Pubitemid 41297224)
17. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD and Cher ML: Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 70: 5558-5566, 2010.
18. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999. (Pubitemid 30666108)
19. Yang Y, Cai S, Yang L, Yu S, Jiang J, Yan X, Zhang H, Liu L, Liu Q, Du J, Cai S and Sung KL: Targeting eradication of malignant cells derived from human bone marrow mesenchymal stromal cells. Exp Cell Res 316: 3329-3341, 2010.
20. Chen X, Wu X, Zhao Y, Wang G, Feng J, Li Q and Qian G: A novel binding protein of single immunoglobulin IL-1 receptor-related molecule: paralemmin-3. Biochem Biophys Res Commun 404: 1029-1033, 2011.
21. Saad F and Lipton A: SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36: 177-184, 2010.
22. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 4: 470-480, 2004.
23. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA and Massague J: Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16: 67-78, 2009.
24. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR and Yoneda T: C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63: 5028-5033, 2003. (Pubitemid 37022641)
25. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci 117: 4619-4628, 2004. (Pubitemid 39433429)
26. Guarino M: Src signaling in cancer invasion. J Cell Physiol 223: 14-26, 2010.
27. Li Y, Wang JP, Santen RJ, Kim TH, Park H, Fan P and Yue W: Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 151: 5146-5156, 2010.
28. Koeneman KS, Yeung F and Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261, 1999. (Pubitemid 29244499)
29. Clezardin P and Teti A: Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24: 599-608, 2007. (Pubitemid 50003596)
30. Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J and Clezardin P: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67: 9894-9902, 2007. (Pubitemid 47621238)